A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer(AJCC) cancer staging system for luminal A breast cancer
Objective: We retrospectively analyzed the clinical prognostic value of the 8th edition of the American Joint Committee on Cancer(AJCC) staging system for luminal A breast cancer.Methods: Using both the anatomic and prognostic staging in the 8th edition of AJCC cancer staging system, we restaged pat...
Gespeichert in:
| Veröffentlicht in: | Chinese journal of cancer research 2017-08, Vol.29 (4), p.351-360 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 360 |
|---|---|
| container_issue | 4 |
| container_start_page | 351 |
| container_title | Chinese journal of cancer research |
| container_volume | 29 |
| creator | Ye, Jingming Wang, Wenjun Xu, Ling Duan, Xuening Cheng, Yuanjia Xin, Ling Zhang, Hong Zhang, Shuang Li, Ting Liu, Yinhua |
| description | Objective: We retrospectively analyzed the clinical prognostic value of the 8th edition of the American Joint Committee on Cancer(AJCC) staging system for luminal A breast cancer.Methods: Using both the anatomic and prognostic staging in the 8th edition of AJCC cancer staging system, we restaged patients with luminal A breast cancer treated at the Breast Disease Center, Peking University First Hospital from 2008 to 2014. Follow-up data including 5-year disease free survival(DFS), overall survival(OS) and other clinic-pathological data were collected to analyze the differences between the two staging subgroups.Results: This study included 421 patients with luminal A breast cancer(median follow-up, 61 months). The 5-year DFS and OS rates were 98.3% and 99.3%, respectively. Significant differences in 5-year DFS but not OS were observed between different anatomic disease stages. Significant differences were observed in both 5-year DFS and OS between different prognostic stages. Application of the prognostic staging system resulted in assignment of 175 of 421 patients(41.6%) to a different group compared to their original anatomic stages. In total, 102 of 103 patients with anatomic stage IIA changed to prognostic stage IB, and 24 of 52 patients with anatomic stage IIB changed to prognostic stage IB, while 1 changed to prognostic stage IIIB. Twenty-two of 33 patients with anatomic stage IIIA were down-staged to IIA when staged by prognostic staging system, and the other 11 patients were down-staged to IIB. Two patients with anatomic stage IIIB were down-staged to IIIA. Among seven patients with anatomic stage IIIC cancer, two were down-staged to IIIA and four were down-staged to stage IIIB.Conclusions: The 8th edition of AJCC prognostic staging system is an important supplement to the breast cancer staging system. More clinical trials are needed to prove its ability to guide selection of proper systemic therapy and predict prognosis of breast cancer. |
| doi_str_mv | 10.21147/j.issn.1000-9604.2017.04.08 |
| format | Article |
| fullrecord | <record><control><sourceid>wanfang_jour_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5592823</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>90726589504849554852484856</cqvip_id><wanfj_id>zgazyj201704008</wanfj_id><sourcerecordid>zgazyj201704008</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-2115c7f5864176bd0ea52d1a03db8ead1979fa6d06fe8cd489fbe5dd2115e49b3</originalsourceid><addsrcrecordid>eNpVUtuK2zAQNaWle2l_oeih0N2HpJJtWRKUhWB6Wxb60j4LWR47CraUleSU7Of0Sysn2dA-zYg5c86MzmTZe4KXOSEl-7hZmhDskmCMF6LC5TLHhC1TxPxFdkmEKBa4KsjLlD9DLrKrEDYYU0YxeZ1d5FyUjFfsMvuzQh6id2ELOpodoK13vXUhGo1gp4ZJReMsUlYN-2ACmoKxPYprQDyuEbTmUHYdWo3gjVYW3TtjI6rdOJoYAVAq18pq8Der-7q-RfrwQCGqfqYK-xBhRJ3zaJhGk3TQCjUeVIgn6JvsVaeGAG9P8Tr79eXzz_rb4uHH1-_16mGhKeZxkT6HatZRXpWEVU2LQdG8JQoXbcNBtUQw0amqxVUHXLclF10DtG3nPihFU1xnd0fe7dSM0Gqw0atBbr0Zld9Lp4z8v2LNWvZuJykVOc-LRPDhSPBb2U7ZXm7c5NNCQT716mm_mX3CJcY8IW9OUt49ThCiHE3QMAzKgpuCJKIscs6YmKGfjlCdTAoeuvNABMvDQciNnA9Czm7L2W05C8kUD0rv_l3q3Px8AQlQnPjXzvaPyZIzRmCWV5QLikteCkpLTvOUcVoVfwH8wMcX</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1943287798</pqid></control><display><type>article</type><title>A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer(AJCC) cancer staging system for luminal A breast cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Ye, Jingming ; Wang, Wenjun ; Xu, Ling ; Duan, Xuening ; Cheng, Yuanjia ; Xin, Ling ; Zhang, Hong ; Zhang, Shuang ; Li, Ting ; Liu, Yinhua</creator><creatorcontrib>Ye, Jingming ; Wang, Wenjun ; Xu, Ling ; Duan, Xuening ; Cheng, Yuanjia ; Xin, Ling ; Zhang, Hong ; Zhang, Shuang ; Li, Ting ; Liu, Yinhua ; Breast Disease Center, Peking University First Hospital, Beijing 100034, China ; General Surgery, Third People's Hospital of Datong City, Datong 037008, China ; Department of Pathology, Peking University First Hospital, Beijing 100034, China</creatorcontrib><description>Objective: We retrospectively analyzed the clinical prognostic value of the 8th edition of the American Joint Committee on Cancer(AJCC) staging system for luminal A breast cancer.Methods: Using both the anatomic and prognostic staging in the 8th edition of AJCC cancer staging system, we restaged patients with luminal A breast cancer treated at the Breast Disease Center, Peking University First Hospital from 2008 to 2014. Follow-up data including 5-year disease free survival(DFS), overall survival(OS) and other clinic-pathological data were collected to analyze the differences between the two staging subgroups.Results: This study included 421 patients with luminal A breast cancer(median follow-up, 61 months). The 5-year DFS and OS rates were 98.3% and 99.3%, respectively. Significant differences in 5-year DFS but not OS were observed between different anatomic disease stages. Significant differences were observed in both 5-year DFS and OS between different prognostic stages. Application of the prognostic staging system resulted in assignment of 175 of 421 patients(41.6%) to a different group compared to their original anatomic stages. In total, 102 of 103 patients with anatomic stage IIA changed to prognostic stage IB, and 24 of 52 patients with anatomic stage IIB changed to prognostic stage IB, while 1 changed to prognostic stage IIIB. Twenty-two of 33 patients with anatomic stage IIIA were down-staged to IIA when staged by prognostic staging system, and the other 11 patients were down-staged to IIB. Two patients with anatomic stage IIIB were down-staged to IIIA. Among seven patients with anatomic stage IIIC cancer, two were down-staged to IIIA and four were down-staged to stage IIIB.Conclusions: The 8th edition of AJCC prognostic staging system is an important supplement to the breast cancer staging system. More clinical trials are needed to prove its ability to guide selection of proper systemic therapy and predict prognosis of breast cancer.</description><identifier>ISSN: 1000-9604</identifier><identifier>EISSN: 1993-0631</identifier><identifier>DOI: 10.21147/j.issn.1000-9604.2017.04.08</identifier><identifier>PMID: 28947867</identifier><language>eng</language><publisher>China: Breast Disease Center, Peking University First Hospital, Beijing 100034, China%General Surgery, Third People's Hospital of Datong City,Datong 037008, China%Department of Pathology, Peking University First Hospital, Beijing 100034, China</publisher><subject>Original</subject><ispartof>Chinese journal of cancer research, 2017-08, Vol.29 (4), p.351-360</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><rights>Copyright © 2017 Chinese Journal of Cancer Research. All rights reserved. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-2115c7f5864176bd0ea52d1a03db8ead1979fa6d06fe8cd489fbe5dd2115e49b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/85190X/85190X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592823/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592823/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28947867$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ye, Jingming</creatorcontrib><creatorcontrib>Wang, Wenjun</creatorcontrib><creatorcontrib>Xu, Ling</creatorcontrib><creatorcontrib>Duan, Xuening</creatorcontrib><creatorcontrib>Cheng, Yuanjia</creatorcontrib><creatorcontrib>Xin, Ling</creatorcontrib><creatorcontrib>Zhang, Hong</creatorcontrib><creatorcontrib>Zhang, Shuang</creatorcontrib><creatorcontrib>Li, Ting</creatorcontrib><creatorcontrib>Liu, Yinhua</creatorcontrib><creatorcontrib>Breast Disease Center, Peking University First Hospital, Beijing 100034, China</creatorcontrib><creatorcontrib>General Surgery, Third People's Hospital of Datong City, Datong 037008, China</creatorcontrib><creatorcontrib>Department of Pathology, Peking University First Hospital, Beijing 100034, China</creatorcontrib><title>A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer(AJCC) cancer staging system for luminal A breast cancer</title><title>Chinese journal of cancer research</title><addtitle>Chinese Journal of Cancer Research</addtitle><description>Objective: We retrospectively analyzed the clinical prognostic value of the 8th edition of the American Joint Committee on Cancer(AJCC) staging system for luminal A breast cancer.Methods: Using both the anatomic and prognostic staging in the 8th edition of AJCC cancer staging system, we restaged patients with luminal A breast cancer treated at the Breast Disease Center, Peking University First Hospital from 2008 to 2014. Follow-up data including 5-year disease free survival(DFS), overall survival(OS) and other clinic-pathological data were collected to analyze the differences between the two staging subgroups.Results: This study included 421 patients with luminal A breast cancer(median follow-up, 61 months). The 5-year DFS and OS rates were 98.3% and 99.3%, respectively. Significant differences in 5-year DFS but not OS were observed between different anatomic disease stages. Significant differences were observed in both 5-year DFS and OS between different prognostic stages. Application of the prognostic staging system resulted in assignment of 175 of 421 patients(41.6%) to a different group compared to their original anatomic stages. In total, 102 of 103 patients with anatomic stage IIA changed to prognostic stage IB, and 24 of 52 patients with anatomic stage IIB changed to prognostic stage IB, while 1 changed to prognostic stage IIIB. Twenty-two of 33 patients with anatomic stage IIIA were down-staged to IIA when staged by prognostic staging system, and the other 11 patients were down-staged to IIB. Two patients with anatomic stage IIIB were down-staged to IIIA. Among seven patients with anatomic stage IIIC cancer, two were down-staged to IIIA and four were down-staged to stage IIIB.Conclusions: The 8th edition of AJCC prognostic staging system is an important supplement to the breast cancer staging system. More clinical trials are needed to prove its ability to guide selection of proper systemic therapy and predict prognosis of breast cancer.</description><subject>Original</subject><issn>1000-9604</issn><issn>1993-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVUtuK2zAQNaWle2l_oeih0N2HpJJtWRKUhWB6Wxb60j4LWR47CraUleSU7Of0Sysn2dA-zYg5c86MzmTZe4KXOSEl-7hZmhDskmCMF6LC5TLHhC1TxPxFdkmEKBa4KsjLlD9DLrKrEDYYU0YxeZ1d5FyUjFfsMvuzQh6id2ELOpodoK13vXUhGo1gp4ZJReMsUlYN-2ACmoKxPYprQDyuEbTmUHYdWo3gjVYW3TtjI6rdOJoYAVAq18pq8Der-7q-RfrwQCGqfqYK-xBhRJ3zaJhGk3TQCjUeVIgn6JvsVaeGAG9P8Tr79eXzz_rb4uHH1-_16mGhKeZxkT6HatZRXpWEVU2LQdG8JQoXbcNBtUQw0amqxVUHXLclF10DtG3nPihFU1xnd0fe7dSM0Gqw0atBbr0Zld9Lp4z8v2LNWvZuJykVOc-LRPDhSPBb2U7ZXm7c5NNCQT716mm_mX3CJcY8IW9OUt49ThCiHE3QMAzKgpuCJKIscs6YmKGfjlCdTAoeuvNABMvDQciNnA9Czm7L2W05C8kUD0rv_l3q3Px8AQlQnPjXzvaPyZIzRmCWV5QLikteCkpLTvOUcVoVfwH8wMcX</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Ye, Jingming</creator><creator>Wang, Wenjun</creator><creator>Xu, Ling</creator><creator>Duan, Xuening</creator><creator>Cheng, Yuanjia</creator><creator>Xin, Ling</creator><creator>Zhang, Hong</creator><creator>Zhang, Shuang</creator><creator>Li, Ting</creator><creator>Liu, Yinhua</creator><general>Breast Disease Center, Peking University First Hospital, Beijing 100034, China%General Surgery, Third People's Hospital of Datong City,Datong 037008, China%Department of Pathology, Peking University First Hospital, Beijing 100034, China</general><general>AME Publishing Company</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>~WA</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope><scope>5PM</scope></search><sort><creationdate>20170801</creationdate><title>A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer(AJCC) cancer staging system for luminal A breast cancer</title><author>Ye, Jingming ; Wang, Wenjun ; Xu, Ling ; Duan, Xuening ; Cheng, Yuanjia ; Xin, Ling ; Zhang, Hong ; Zhang, Shuang ; Li, Ting ; Liu, Yinhua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-2115c7f5864176bd0ea52d1a03db8ead1979fa6d06fe8cd489fbe5dd2115e49b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ye, Jingming</creatorcontrib><creatorcontrib>Wang, Wenjun</creatorcontrib><creatorcontrib>Xu, Ling</creatorcontrib><creatorcontrib>Duan, Xuening</creatorcontrib><creatorcontrib>Cheng, Yuanjia</creatorcontrib><creatorcontrib>Xin, Ling</creatorcontrib><creatorcontrib>Zhang, Hong</creatorcontrib><creatorcontrib>Zhang, Shuang</creatorcontrib><creatorcontrib>Li, Ting</creatorcontrib><creatorcontrib>Liu, Yinhua</creatorcontrib><creatorcontrib>Breast Disease Center, Peking University First Hospital, Beijing 100034, China</creatorcontrib><creatorcontrib>General Surgery, Third People's Hospital of Datong City, Datong 037008, China</creatorcontrib><creatorcontrib>Department of Pathology, Peking University First Hospital, Beijing 100034, China</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Chinese journal of cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ye, Jingming</au><au>Wang, Wenjun</au><au>Xu, Ling</au><au>Duan, Xuening</au><au>Cheng, Yuanjia</au><au>Xin, Ling</au><au>Zhang, Hong</au><au>Zhang, Shuang</au><au>Li, Ting</au><au>Liu, Yinhua</au><aucorp>Breast Disease Center, Peking University First Hospital, Beijing 100034, China</aucorp><aucorp>General Surgery, Third People's Hospital of Datong City, Datong 037008, China</aucorp><aucorp>Department of Pathology, Peking University First Hospital, Beijing 100034, China</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer(AJCC) cancer staging system for luminal A breast cancer</atitle><jtitle>Chinese journal of cancer research</jtitle><addtitle>Chinese Journal of Cancer Research</addtitle><date>2017-08-01</date><risdate>2017</risdate><volume>29</volume><issue>4</issue><spage>351</spage><epage>360</epage><pages>351-360</pages><issn>1000-9604</issn><eissn>1993-0631</eissn><abstract>Objective: We retrospectively analyzed the clinical prognostic value of the 8th edition of the American Joint Committee on Cancer(AJCC) staging system for luminal A breast cancer.Methods: Using both the anatomic and prognostic staging in the 8th edition of AJCC cancer staging system, we restaged patients with luminal A breast cancer treated at the Breast Disease Center, Peking University First Hospital from 2008 to 2014. Follow-up data including 5-year disease free survival(DFS), overall survival(OS) and other clinic-pathological data were collected to analyze the differences between the two staging subgroups.Results: This study included 421 patients with luminal A breast cancer(median follow-up, 61 months). The 5-year DFS and OS rates were 98.3% and 99.3%, respectively. Significant differences in 5-year DFS but not OS were observed between different anatomic disease stages. Significant differences were observed in both 5-year DFS and OS between different prognostic stages. Application of the prognostic staging system resulted in assignment of 175 of 421 patients(41.6%) to a different group compared to their original anatomic stages. In total, 102 of 103 patients with anatomic stage IIA changed to prognostic stage IB, and 24 of 52 patients with anatomic stage IIB changed to prognostic stage IB, while 1 changed to prognostic stage IIIB. Twenty-two of 33 patients with anatomic stage IIIA were down-staged to IIA when staged by prognostic staging system, and the other 11 patients were down-staged to IIB. Two patients with anatomic stage IIIB were down-staged to IIIA. Among seven patients with anatomic stage IIIC cancer, two were down-staged to IIIA and four were down-staged to stage IIIB.Conclusions: The 8th edition of AJCC prognostic staging system is an important supplement to the breast cancer staging system. More clinical trials are needed to prove its ability to guide selection of proper systemic therapy and predict prognosis of breast cancer.</abstract><cop>China</cop><pub>Breast Disease Center, Peking University First Hospital, Beijing 100034, China%General Surgery, Third People's Hospital of Datong City,Datong 037008, China%Department of Pathology, Peking University First Hospital, Beijing 100034, China</pub><pmid>28947867</pmid><doi>10.21147/j.issn.1000-9604.2017.04.08</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1000-9604 |
| ispartof | Chinese journal of cancer research, 2017-08, Vol.29 (4), p.351-360 |
| issn | 1000-9604 1993-0631 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5592823 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Original |
| title | A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer(AJCC) cancer staging system for luminal A breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T20%3A04%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20retrospective%20prognostic%20evaluation%20analysis%20using%20the%208th%20edition%20of%20American%20Joint%20Committee%20on%20Cancer(AJCC)%20cancer%20staging%20system%20for%20luminal%20A%20breast%20cancer&rft.jtitle=Chinese%20journal%20of%20cancer%20research&rft.au=Ye,%20Jingming&rft.aucorp=Breast%20Disease%20Center,%20Peking%20University%20First%20Hospital,%20Beijing%20100034,%20China&rft.date=2017-08-01&rft.volume=29&rft.issue=4&rft.spage=351&rft.epage=360&rft.pages=351-360&rft.issn=1000-9604&rft.eissn=1993-0631&rft_id=info:doi/10.21147/j.issn.1000-9604.2017.04.08&rft_dat=%3Cwanfang_jour_pubme%3Ezgazyj201704008%3C/wanfang_jour_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1943287798&rft_id=info:pmid/28947867&rft_cqvip_id=90726589504849554852484856&rft_wanfj_id=zgazyj201704008&rfr_iscdi=true |